Get the Stockscreener App
32.16
1.17%
-0.435
Bridgebio Pharma Inc stock is traded at $32.16, with a volume of 517.73K.
It is down -1.17% in the last 24 hours and up +2.06% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$32.59
Open:
$32.37
24h Volume:
517.73K
Relative Volume:
0.20
Market Cap:
$6.17B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-13.34
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
-0.06%
1M Performance:
+2.06%
6M Performance:
+23.03%
1Y Performance:
+14.34%
1-Day Range:
$32.07
$32.82
1-Week Range:
$30.55
$33.19
52-Week Range:
$21.62
$39.47
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
32.24 | 6.17B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.68 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.50 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.21 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.18 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.47 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Pharma’s SWOT analysis: innovative pipeline drives stock potential - Investing.com India
BridgeBio Pharma director Hannah Valantine sells $419,499 in stock - Investing.com
Genetic Disorder L.P. Kkr Sells 6,000,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - Defense World
Kkr sells $197.76 million in BridgeBio Pharma stock By Investing.com - Investing.com Australia
(BBIO) On The My Stocks Page - Stock Traders Daily
Major Stakeholder Sells Millions in BridgeBio Pharma Stock! - TipRanks
BridgeBio Shares Fall After KKR Genetic Disorder Sells 6 Million Shares -March 06, 2025 at 09:54 am EST - Marketscreener.com
Cantor Fitzgerald maintains $95 target on BridgeBio Pharma stock - Investing.com
BridgeBio prices $575M convertible notes offering - TipRanks
The 4.5% return this week takes BridgeBio Pharma's (NASDAQ:BBIO) shareholders three-year gains to 308% - Simply Wall St
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why - The Globe and Mail
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
Prediction: BridgeBio Pharma Will Beat The Market. Here's Why - Barchart
Leerink Partnrs Has Optimistic Outlook of BBIO Q1 Earnings - MarketBeat
Y Intercept Hong Kong Ltd Increases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
What is Leerink Partnrs' Forecast for BBIO Q3 Earnings? - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownTime to Sell? - MarketBeat
Q1 Earnings Estimate for BBIO Issued By Leerink Partnrs - MarketBeat
Brian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares - MarketBeat
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Citeline News & Insights
BridgeBio Pharma Strengthens Financial Position with Note Issuance - TipRanks
BridgeBio Pharma Issues $575 Million Of 1.75% Convertible Senior Notes Due 2031 - Marketscreener.com
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - MedCity News
BridgeBio Pharma, NetApp, Talen Energy - TradingView
Raymond James resumes coverage on BridgeBio with 'outperform' on heart drug optimism - TradingView
BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive
BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go publicSan Francisco Business Times - The Business Journals
Helix Acquisition to Merge With BridgeBio Oncology Therapeutics -February 28, 2025 at 09:37 am EST - Marketscreener.com
$450M Deal Powers New Cancer-Fighting Biotech: What's Inside BridgeBio's Oncology SPAC Merger? - StockTitan
BridgeBio price target raised to $46 from $45 at BofA - TipRanks
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsBBIO - ACCESS Newswire
BridgeBio prices offering of $500 million convertible senior notes due 2031 - MSN
BridgeBio Pharma CFO Brian Stephenson sells $282,114 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $2.52 million in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Bayer Execs Roth And Eckhardt On Current And Future Pharma Growth - Scrip
BridgeBio Pharma CFO Brian Stephenson sells $282,114 in stock - Investing.com India
BridgeBio Pharma CEO Neil Kumar sells $2.52 million in stock - Investing.com India
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
BridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Principal Financial Group Inc. Reduces Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Rhumbline Advisers Acquires 5,007 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
Watkins Advises on BridgeBio’s US$500 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
BridgeBio up after $500 mln convertible debt deal priced - TradingView
BridgeBio Pharma Prices $500 Million Convertible Senior Notes Offering -February 26, 2025 at 05:59 am EST - Marketscreener.com
How BridgeBio's $500M Debt Refinancing Could Strengthen Its Financial Future - StockTitan
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt - GlobeNewswire
When the Price of (BBIO) Talks, People Listen - Stock Traders Daily
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Valantine Hannah | Director |
Mar 06 '25 |
Sale |
32.58 |
12,875 |
419,500 |
1,764 |
| KKR Genetic Disorder L.P. | 10% Owner |
Mar 05 '25 |
Sale |
32.96 |
6,000,000 |
197,760,000 |
19,260,971 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):